SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 57386.
  • 2
    Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 6317.
  • 3
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 2639.
  • 4
    Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 14439.
  • 5
    National Committee for Quality Assurance (NCQA), Physician Consortium for Performance Improvement (PCPI), American College of Rheumatology (ACR). Rheumatoid arthritis physician performance measurement set. 2008. URL: http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/rheumatoid-arthritis.pdf.
  • 6
    Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology [editorial]. J Rheumatol 1998; 25: 1989.
  • 7
    Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) global assessment of disease activity, Disease Activity Score (DAS) and Disease Activity Score with 28-joint counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), patient-based Disease Activity Score with ESR (PDAS1) and patient-based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken) 2011; 63 Suppl: S1436.
  • 8
    Lansbury J. Quantitation of the activity of rheumatoid arthritis. 5. A method for summation of the systemic indices of rheumatoid activity. Am J Med Sci 1956; 232: 30010.
  • 9
    Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 62539.
  • 10
    Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005; 32: 24105.
  • 11
    Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to Disease Activity Score and Clinical Disease Activity Index categories. J Rheumatol 2008; 35: 213647.
  • 12
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 72940.
  • 13
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 14
    Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004; 50: 3296305.
  • 15
    Pincus T, Yazici Y, Bergman M. Development of a Multi-dimensional Health Assessment Questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol 2005; 23 Suppl: S1928.
  • 16
    Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001; 28: 892903.
  • 17
    Marhadour T, Jousse-Joulin S, Chales G, Grange L, Hacquard C, Loeuille D, et al. Reproducibility of joint swelling assessments in long-lasting rheumatoid arthritis: influence on Disease Activity Score-28 values (SEA-Repro study part I). J Rheumatol 2010; 37: 9327.
  • 18
    Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003; 48: 275062.
  • 19
    Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 153042.
  • 20
    Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 107282.
  • 21
    Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis. Work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998; 25: 210817.
  • 22
    Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796806.
  • 23
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 24457.
  • 24
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 25
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010; 69: 659.
  • 26
    Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006; 24 Suppl: S2932.
  • 27
    Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011; 63: 4352.
  • 28
    Hensor EM, Emery P, Bingham SJ, Conaghan PG. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? Rheumatology (Oxford) 2010; 49: 15219.